The levers that actually moved numbers this week were upstream and unglamorous: sugar exposure before age two, a supermarket multivitamin at sixty, a thymus peptide that fades before midlife, and a gut bacterium that tracked the pace of aging when the famous epigenetic clocks did not.

Early-life sugar rationing linked to 23% lower dementia risk and 2.6-year delay [American Academy of Neurology]

Researchers at The Hong Kong University of Science and Technology in Guangzhou, China leveraged Britain's wartime sugar rationing as a natural experiment with 64,737 people, beginning when participants averaged age 55 and tracking dementia diagnoses up to 15 years later via medical records. Those exposed to rationing before birth and up to one year showed 21% lower dementia risk; those exposed up to two years old showed 23% lower dementia risk and 2.6-year delayed onset, after adjusting for age, sex, and health factors. A smaller brain-scan subgroup showed less sugar early in life was associated with higher total gray matter volume and lower white matter hyperintensities, a marker of brain tissue damage. The study does not prove that lower sugar consumption directly prevents dementia—it only shows an association, and was observational research that relied on past events rather than following people over time.

Daily multivitamin associated with better functional health over 3 years in 16,000 adults 60+ [EurekAlert]

A secondary analysis of the COSMOS trial examined over 16,000 participants aged 60 and older who were randomized to daily multivitamin, cocoa extract supplement, both, or placebo. After 3 years, the multivitamin group scored significantly higher on the Kansas City Cardiomyopathy Questionnaire, with the greatest differences in symptom burden and clinical summary score. Cocoa extract did not significantly change functional health scores in the overall population, although it provided a significant benefit in patients with congestive heart failure. This is a human randomized controlled trial, but the findings are preliminary and have not undergone full journal peer review; they were presented at NUTRITION 2026 in July as an abstract. The presenter, Bayu B. Bekele, emphasized that a multivitamin “is not a substitute for a good diet or exercise.”

Thymulin, a fading thymus peptide, suppresses pro-inflammatory aging in mouse models [Nature Communications]

Researchers showed aged mice and humans accumulate pro-inflammatory myeloid cells (IL-1α, IL-1β, IL-6, TNF-α) enriched in the breast tumor microenvironment. Using heterochronic parabiosis and bone marrow chimeras, they found that non-bone-marrow-derived circulating factors in young hosts suppress this myeloid activation. Thymulin, a thymus-derived peptide that declines with age, emerged as this suppressive mediator; in mouse models it inhibited NF-κB signaling, enhanced antitumor T-cell immunity, improved tumor control and survival, and sensitized tumors to anti-PD-L1 therapy in an age-dependent manner. In our read, this is what a peptide with real data looks like, and it is still only mouse data, not a human-validated therapeutic.

Gut microbiome predicted DunedinPACE (R² 0.152), but not epigenetic clock residuals [Scientific Reports]

Using 16S rRNA sequencing and DNA methylation from 123 monocyte-enriched samples in a cohort including Native Hawaiian and Pacific Islander participants, researchers tested whether the gut microbiome could predict aging better than famous epigenetic clocks (Horvath, Levine, GrimAge2). Models predicting residuals of these traditional clocks showed no predictive signal at either taxonomic rank. The microbiome-derived proof-of-concept EpiBiome-Accel model for DunedinPACE, however, reached statistical significance at species level (R² = 0.152, ρ = 0.408, p = 0.012; permutation p < 0.001) and genus level (R² = 0.099, permutation p = 0.036). Adding chronological age actually worsened performance (ΔR² = −0.046 at species level), indicating age-independence of the microbiome signal. Bifidobacterium adolescentis was the strongest predictor of decelerated aging; Succinivibrio dextrinosolvens the strongest association with accelerated aging. The authors caution these taxa are “hypothesis-generating candidates for mechanistic follow-up, rather than as individual-level diagnostic markers,” so association does not imply causation or individual-level predictive value.

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

LDL fell 13.2% on the tablet and rose 1.6% on placebo over 12 weeks [Nutrients]

HUMAN randomized, double-blind, placebo-controlled, parallel-group trial. Ninety adults with low-to-moderate cardiovascular risk and elevated LDL-C were randomized to NUT2 (n = 45) or placebo (n = 45), one tablet daily for 12 weeks alongside standardized dietary advice. The formulation is worth reading closely, because it is the sum of six things biohackers already buy separately: artichoke extract 100 mg, bergamot extract 300 mg (equivalent to flavonoids 120 mg), Berberis aristata extract 588 mg, astaxanthin 0.50 mg, folic acid 0.20 mg and chromium 0.04 mg.

At week 12 the baseline-corrected between-group difference in LDL-C was −23 mg/dL (95% CI −29 to −16; p < 0.001), and total cholesterol fell by a corrected −26 mg/dL (95% CI −36 to −17; p < 0.001). Homocysteine was significantly reduced and fasting insulin concentrations were lower, and metabolic syndrome prevalence at week 12 was 13.3% with NUT2 versus 37.8% with placebo (p = 0.008) — which the authors themselves flag as exploratory and based on small participant numbers. There was no significant between-group difference in hsCRP. Three caveats belong next to that 23 mg/dL: the study was funded by Meda Pharma S.p.A. (the product sits in the Armolipid brand, now owned by Cooper Consumer Health) and two authors are company employees; baseline lipid values differed between the groups, which is why every headline number is baseline-corrected; and although ethics approval dates to 13 January 2020, the ClinicalTrials.gov registration (NCT07492264) is dated 23 March 2026.

HR 0.42 for cardiovascular death among patients who kept exercising after coronary disease [Nutrients]

HUMAN systematic review and meta-analysis, and by a wide margin the largest evidence base in this issue: 40 reports representing 34 data sources and at least 260,354 unique patients with coronary heart disease, comprising six randomized trials, 30 observational reports and four comparative nonrandomized studies, searched from January 2015 through 15 June 2026.

Maintained or continued physical activity relative to persistent inactivity carried a hazard ratio of 0.64 for all-cause mortality (95% CI 0.55 to 0.74; I² = 29%) and 0.42 for cardiovascular mortality (95% CI 0.28 to 0.64; I² = 72%). Closer Mediterranean diet adherence was inversely associated with all-cause mortality (HR 0.74, 95% CI 0.60 to 0.90; I² = 44%), while cardiovascular mortality for diet remained uncertain. The single randomized comparison of a Mediterranean versus a low-fat diet gave an HR of 0.72 for major adverse cardiovascular events (95% CI 0.54 to 0.96; moderate certainty). Two things to hold onto: 30 of the 40 reports are observational and only six are randomized, so the physical-activity hazard ratios rest largely on comparisons between people who kept exercising and people who stopped rather than on assignment; and the I² of 72% on that 0.42 signals substantial heterogeneity between studies. The authors’ own conclusion is that randomized evidence on exercise or combined dietary and activity programs was sparse.

Bitter melon protein tracked with a 0.23% HbA1c drop — only in metformin users [Nutrients]

Two studies in one paper. The ANIMAL arm used db/db mice: a bitter melon blood-sugar-modulating protein (BMP) significantly reduced fasting blood glucose and HbA1c, with greater glucose-lowering when combined with metformin than metformin alone (approximately 300 mg/dL versus 200 mg/dL reduction; p < 0.05), and skeletal muscle transcriptomics identified 27 shared pathways involved in glucose and lipid metabolism.

The HUMAN arm is an exploratory, retrospective, self-controlled observational cohort of 119 individuals with prediabetes or diabetes taking daily BMP for three months. Among metformin users, BMP supplementation was associated with an HbA1c reduction of 0.23% (p = 0.0028), total cholesterol −7.5 mg/dL and LDL cholesterol −6.1 mg/dL; the largest observed HbA1c reduction, 0.32% (p < 0.0001), occurred in participants on 1000 mg/day of metformin. In non-users, no significant changes were observed. The authors state plainly that given the retrospective self-controlled design and baseline clinical differences between treatment groups, these clinical findings reflect observational associations rather than causal effects. That interaction pattern — a botanical whose association with better numbers showed up only alongside a drug — is the part worth filing away.

Creatine kinase 121.52 on sulforaphane versus 291.84 on placebo, in 14 people [Nutrients]

HUMAN double-blind, placebo-controlled crossover trial, and the authors label it “Proof of Principle” for a reason. Fourteen healthy participants (7 male, 7 female; age 25.07 ± 1.04 years) took sulforaphane glucosinolate capsules at 200 µmol/day or placebo for two weeks, crossed over after a three-week washout, and performed a maximal exercise test after each period.

Sulforaphane did not alter endurance capacity or blood cell counts. It did attenuate serum creatine kinase (p = 0.034; sulforaphane 121.52 ± 16.89, placebo 291.84 ± 133.07) and myoglobin (p = 0.011; sulforaphane 15.82 ± 1.95, placebo 27.31 ± 5.71) after exercise; in the discussion the estimated marginal means for myoglobin were 17.81 (95% CI 13.35–22.27) on sulforaphane versus 26.47 (95% CI 22.01–30.94) on placebo. Absolute oxidative stress markers showed no significant change, and the significant supplement interactions appeared only in percent change from baseline for the d-ROMs (p = 0.038) and OXY-adsorbent (p = 0.032) tests. Read the dispersion before the means: the placebo creatine kinase standard deviation of 133.07 is close to half its own mean, n is 14, the abstract reports these values without units, and the authors state that the study received funding from Murakami Farm Co., Ltd.

Hesperetin restored a longevity gene in aged mouse liver — no effect sizes published [npj Aging]

ANIMAL study in naturally aged mice, plus human liver tissue for validation. Late-life administration of the citrus flavonoid hesperetin restored hepatic Cisd2 expression, improved liver pathology, and partially reversed aging-associated transcriptomic alterations. Mechanistically the authors identify Hmgcs2 as a candidate molecular target of hesperetin and show that Hmgcs2 interacts with Pparα to activate Cisd2 transcription through a Ppar response element in the Cisd2 promoter; the protective effects are largely Cisd2-dependent, being significantly attenuated in hepatocyte-specific Cisd2 knockout mice. PPARα and CISD2 expression decline with age in human liver tissues.

The reason this gets a mechanism in the headline instead of a number is that it does not publish one. This is an unedited early-access manuscript, and the abstract carries no effect sizes, no doses and no animal numbers — so there is nothing here to translate into a human quantity, and “late-life administration” in a mouse has no defined equivalent in a person. What it does establish is a specific, testable axis (Hmgcs2 → Pparα → Cisd2) that a citrus flavonoid appears to engage in an aged liver, which is a more useful thing to watch than another correlation.

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

Eight-hour eating window predicted sharper spatial planning [American Society for Nutrition]

Forty-seven women aged 50–79, overweight or obese, were counseled to cut 500 calories daily; 26 of the 47 restricted eating to less than 9 hours (typically 10 a.m.–6 p.m., averaging 8.2 hours versus 12.3 hours). This was a preliminary human pilot trial presented at NUTRITION 2026, not yet peer-reviewed. After six months, both groups lost about 15 pounds, yet the time-restricted group showed significant improvements on spatial planning and problem-solving tests and a trend toward fewer memory and learning errors; no significant difference on multitasking or reaction time tests. Principal investigator Sue Shapses noted: “There was a modest effect of time-restricted eating to improve spatial planning and problem-solving and on reducing errors related to memory and learning.” Since both groups achieved about the same weight loss, in our read, the cognitive differences appear linked to the eating window duration rather than to the calorie deficit alone.

Mutated blood cells linked to 2.84-year epigenetic age acceleration (Horvath1Age IEAA) [Fight Aging]

A meta-analysis of existing studies examining clonal haematopoiesis of indeterminate potential (CHIP)—where blood stem cells acquire mutations and one clone expands—found a consistent link between CHIP and epigenetic age acceleration. The analysis pooled data from five studies comprising 7,483 individuals (aged 55–79, 67.1% female); three cross-sectional studies (n=6,946) showed that people with CHIP had higher epigenetic age acceleration compared with people without CHIP, ranging from 1.20 years (GrimAge) to 2.84 years (Horvath1Age) depending on the clock used. Larger clones were associated with greater epigenetic age acceleration, and mutations in the TET2 gene showed larger and more consistent effects than DNMT3A mutations. Importantly, this is an association, not proof of causation, and larger longitudinal studies are needed to verify a temporal relationship. The implication: a portion of what your epigenetic clock reads as “age” may arise from mutated blood cells rather than aging in your tissues overall.

Immune traps at 4 mg/L killed cultured human skin cells [Lifespan.io]

Neutrophil extracellular traps (NETs) are DNA and protein structures released when neutrophils self-destruct to trap pathogens. In human tissue, samples from patients with actinic keratosis or chronic actinic dermatitis (sun-damage conditions) contained more NETs compared with controls. In mice exposed to UVB, treatment with GSK484 (inhibiting PAD4, required for NET formation) produced much less visible skin damage and reduced skin erosion, while skin thickening, inflammatory biomarkers, and measurements of oxidative stress were all significantly reduced compared with untreated mice, though protection was incomplete; in vitro, skin cells exposed to 4 milligrams per liter of NETs showed cell death and inflammation, whereas degrading NETs first with DNase I substantially reduced these effects. Blocking CCDC25 (a gene making cells responsive to NETs) in UVB-exposed mice produced results similar to GSK484. In sum, in our read, immune response to sun exposure appears partly responsible for the damage itself.

Young mice show twice the autophagic flux of old mice under toxin stress [Lifespan.io]

In mice given LPS (a toxin inducing acute kidney injury), older mice (18 months) sustained more kidney damage than younger mice (2 months), measured by creatinine, BUN, and tubular injury; older mice did not significantly upregulate LC3 (autophagy marker) in response, while younger mice showed autophagic flux twice as high. In cell experiments, senescent kidney cells failed to activate autophagy when exposed to the toxin, whereas normal cells activated it readily; a peptide inducing autophagy (Tat-Beclin 1) reduced LPS damage, while chloroquine (blocking autophagy) worsened damage and senescence. In older mice, a curcumin analog called C1—which increases the nuclear translocation of TFEB, a regulator of autophagy downregulated in aging kidneys—partially but significantly reduced creatinine, BUN, and NGAL. Note: C1 is a research compound, not culinary turmeric, tested in acutely poisoned mice; this work “may not reflect conditions for real kidney patients.” The core finding: aging kidneys’ vulnerability to toxins may reflect a failure to activate cleanup under stress, not simply tissue wear.

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

The biology moves faster than our readouts—this week showed intracellular NAD spiking 53% while plasma levels stayed flat, blood proteins flagging liver disease more than a decade before diagnosis, and cartilage degenerating at the molecular level while the radiographs still looked unchanged.

Whole-blood NAD rises 53% in five days, plasma NAD does not [GeroScience]

A double-blind human trial randomized 60 participants, with 50 in the primary analysis (23 on LNAD+, 27 on placebo). Five days of 2,000 mg daily NAD+ raised intracellular NAD measured in whole blood 53% by day 6 (Hedges' g = 3.66, p = 5.48 × 10⁻¹⁴), while circulating NAD measured in plasma did not move (p = 0.60). The 53% rise is predominantly a red blood cell signal, not a measurement of muscle or tissue NAD, yet the effect was clear in cells—78.3% of participants exceeded a 30% increase. Prior trials reported whole-blood NAD rises of 22–100% with nicotinamide riboside and 11–60% with nicotinamide mononucleotide, typically over 2–12 weeks. The trial ran five days, no clinical endpoints survived multiplicity correction, and it was retrospectively registered, so this is evidence that the formulation reaches cells, not evidence of benefit.

Five blood proteins spot liver fat risk up to 16 years early [Nature Aging]

A human cohort study across 50,000+ participants (Southern UK, Northern UK, EPIC-Norfolk, Southern China) identified a five-protein panel (FUOM, ACY1, KRT18, CDHR2, GGT1) that predicts metabolic dysfunction-associated steatotic liver disease up to 16 years before clinical onset, with a 16.6-year AUC of 0.756 and 5-year AUC of 0.838. This is a prediction model only—no treatment was tested and no improvement in outcomes was demonstrated. The result illustrates the core finding of this week's research: biology moves first, measurement follows, and clinical detection lags years behind both.

Among 117,163 adults free of chronic conditions, 32.8% were already prefrail [GeroScience]

A human observational study of 117,163 UK Biobank adults (mean age 53.9 ± 8.0 years, free of known chronic conditions) tested 29 physiological markers against the Fried Frailty Phenotype, finding that higher body fat %, waist-to-hip ratio, triglycerides, gamma-glutamyl transferase, alkaline phosphatase, cystatin C, HbA1c, hsCRP, and white blood cell count were associated with frailty, while higher blood pressure, lung function, bilirubin, and IGF-1 were inversely associated with frailty. Of the cohort, 1.1% were frail and 32.8% prefrail. This is observational—associations do not prove causation—but the data suggest early physiological dysregulation preceding clinically manifest chronic disease.

67.4% vs 30.0% gained physical performance, not cognition, in 3 months [GeroScience]

A human randomized trial of 188 older adults (over 75 years) with mild cognitive impairment; 46 intervention and 72 control participants were included in the analyses. The intervention group completed 3 months of home-based multicomponent exercise (3–5 days per week, based on Vivifrail), finding that 89.1% of the exercise group showed a clinically meaningful response on at least one outcome (OR = 4.82 [95% CI 1.56–14.88], p = 0.006). However, gains were concentrated in one domain: the short physical performance battery (SPPB), where 67.4% improved versus 30.0% of controls (OR 5.05, p = 0.001). No between-group differences emerged for depression (GDS), cognition (MMSE), handgrip strength, or functional ability (Barthel Index), with response rates all below 40% and p > 0.05.

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

Vegan vs. Meat-Rich Diets Shift Methylation in 48 Adults After Four Weeks [EurekAlert]

After one week on a standardized diet, 48 healthy adults were randomly assigned to either a vegan or meat-rich diet for one month, matched for calories. Researchers examined more than 800,000 DNA methylation sites and found measurable epigenetic shifts within four weeks. However, the study was relatively small, lasted only one month, the methylation changes were modest and spread across hundreds of thousands of sites, and the findings do not demonstrate that a vegan diet prevents cancer or reverses aging. Jerome Mertens, PhD, of UC San Diego School of Medicine, noted: “It’s that the epigenome responded measurably in just four weeks, showing that our biology is far more dynamic — and responsive to everyday choices — than we often assume.” (HUMAN randomized trial)

Reduced Cardiac Output Predicts Brain Atrophy in APOE-e4 Carriers Over 11 Years [EurekAlert]

In a longitudinal study of 756 adults ages 50–92, researchers at Vanderbilt Health followed participants over 11 years to examine whether reduced cardiac output could lead to adverse brain health outcomes even in the absence of cardiovascular disease. Among APOE-e4 carriers—people with a genetic variant that increases Alzheimer’s risk—lower cardiac output at baseline was associated with smaller brain volumes, particularly in the temporal and occipital lobes, and predicted greater temporal lobe atrophy over time. According to the study’s first author, Elizabeth Moore, MD, PhD, this was among the first investigations to determine how APOE-e4 genotype modifies the associations between subclinical cardiac dysfunction and neurodegeneration. This is an association, not a demonstration of causation. (HUMAN observational)

DNA Aging Clocks Lose Reliability With Meals and Stress [Lifespan.io]

DNA aging clocks showed high technical reliability in the laboratory—the same input reliably produced the same output. Under biological conditions, however, they became unreliable: meals caused most to yield very different results (only the PC version of the original GrimAge remained within the ‘good’ range), version 2 of GrimAge was very poorly reliable, no clock achieved ‘good’ reliability under stress, and pollution and altitude similarly degraded reliability. Published in Aging Cell, this methods evaluation of DNA-methylation biomarkers was based on work where many of the authors’ findings were generated using young-adult cohorts, and the analysis lacked separate control groups. In our read, individual measurements may reflect acute stress, meals, or environmental exposure rather than your true biological age trajectory. (methods/reliability evaluation of DNA-methylation biomarkers)

Valine Restriction Extends Male Mouse Median Lifespan by 23.4% [Lifespan.io]

Mice on a lifelong diet containing 67% less valine showed striking sex differences: male median lifespan increased 23.4% (from 777 to 959 days), while female lifespan showed minimal change (842 days in controls versus 850 days with valine restriction, <1% increase). Valine restriction maintained marked leanness in both sexes throughout adulthood, improved glucose tolerance in males from early adulthood through 24 months and across most of the female lifespan, and reduced senescence-associated staining and gene-expression signatures in liver, kidney, and adipose tissue, although some senescence markers actually moved in the opposite direction. Valine restriction increased mTOR signaling in male liver despite extending lifespan; in our read, this challenges prior assumptions about mTOR’s role in longevity. Published in Nature Aging, Dr. Dudley Lamming suggested females “might benefit from valine restriction under other conditions, such as a different degree of restriction, started at another time in life, or on a different genetic background.” (ANIMAL—mice)

Persistent Low Income Associated With Larger Ventricles at Ages 69–71 [News-Medical]

In the MRC 1946 British birth cohort of 5,362 individuals, 2,759 participants were assessed for household income at ages 26, 43, and 53, and for self-reported financial hardships at ages 36, 43, and 53; cognitive function was measured at ages 53, 63, and 69. Among these 2,759 participants, 16% experienced persistent low household income and 12% experienced persistent financial hardships. Greater cumulative exposure to persistent low household income was associated with larger ventricular volume at ages 69–71, and men with persistent low income performed worse on processing speed at age 53 than women. The neuroimaging subsample was modest (369 participants completed follow-up), the findings were exploratory, and the authors noted selective attrition and limited ethnic diversity. Subgroup interactions require replication, and the findings do not demonstrate that addressing financial hardship will safeguard brain health or enhance quality of life. (HUMAN observational)

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

Education affects 86% in China, 12% in the US — dementia's geography [USC / The Lancet Healthy Longevity]

A study of more than 214,000 older adults across 14 countries and regions (2009–2023) analyzed 12 modifiable dementia risk factors — a human, observational analysis. USC-led researchers found stark geographic disparities: low education affected 86% of older Chinese adults but only 12% in the US; high BMI affected 45% of Americans versus 13% in India. The takeaway: dementia prevention isn't predetermined or one-size-fits-all. Which factors dominate depends on where you live, so the highest-yield prevention targets differ from person to person.

Improving lifestyle habits cut cognitive impairment risk by 63% in older adults [Archives of Public Health]

A 6,765-person human prospective cohort from the Chinese Longitudinal Healthy Longevity Survey tracked lifestyle changes (diet, sleep, physical/cognitive/social activity) from 2008–2014 and measured cognitive outcomes via MMSE 2014–2018 (mean 5.9-year follow-up). Of the cohort, 1,659 (24.5%) developed cognitive impairment. Compared to the Low-Declining trajectory group, those whose lifestyles improved (Moderate-Improving class) showed a 63% lower risk (HR 0.368, 95% CI 0.269–0.396) — and onset was delayed by +6.433 years. The signal wasn't intensity of activity — it was the direction of change; in our read, that's an encouraging (if observational) sign that upgrading habits later still counts.

Boosting the mitochondrial enzyme SIRT3 eased disc degeneration in aged mice [Fight Aging / Experimental Gerontology]

In mouse studies, Sirt3-knockout mice exhibited severe disc degeneration with increased inflammation and senescence. In a D-galactose-induced aging model, the SIRT3 activator 2-APQC significantly ameliorated degeneration, restoring mitochondrial function and reducing inflammation and cellular senescence. In human disc tissue, SIRT3 expression inversely correlates with degeneration — suggesting the mechanism is relevant to human aging. Disc degeneration and back pain map to mitochondrial decline, a recurring aging lever across multiple tissues; SIRT3 is a target to watch. Note: 2-APQC is research-only, not available to consumers.

Click here to share your thoughts

This newsletter is for informational purposes only and is not medical advice. Consult your physician before changing your protocol.

Two BCG shots reshaped brain immunity and cut CSF amyloid in 12 pre-symptomatic adults [Communications Medicine]

Researchers ran two small, year-long open-label trials in adults 55 and older — 12 with no signs of Alzheimer's pathology and 11 who already had biomarker evidence of disease — giving each person two intradermal BCG shots a month apart. BCG, the century-old tuberculosis vaccine, is the best-studied trigger of "trained immunity," a durable reprogramming of the innate immune system. In the cerebrospinal fluid, BCG produced persistent, trained-immunity-like changes in immune cells that looked different from those in blood, hinting at brain-specific imprinting. In the participants without existing pathology, cerebrospinal-fluid amyloid-beta fell while blood amyloid-beta rose — the direction you would want if the brain were clearing the protein — with no unexpected safety signals. The catch: none of this appeared in people who already had Alzheimer's biomarkers, and 23 participants is far too few to change anything. For your protocol: it is too early to chase BCG for the brain, but this is the strongest human hint yet that immune "training" reaches the central nervous system, and it makes the early, pre-symptomatic window the one that matters.

A gut bacterial byproduct tracked worse brain aging across 1,196 adults [Nature Communications]

This one is a caution, not a supplement to add. Imidazole propionate (ImP) is a metabolite that certain gut bacteria pump out — more of it when diet and metabolism skew toward insulin resistance — and it was already linked to atherosclerosis. In a cohort of 1,196 cognitively healthy adults, higher blood ImP tracked with lower cognitive scores and worse dementia biomarkers, both at baseline and over time. A genome-wide analysis then pinned a chromosome-12 locus to both ImP levels and Alzheimer's risk, pointing to cause rather than coincidence, and in mice chronic ImP degraded the blood-brain barrier and drove tau tangles. The damage ran through the enzyme GSK-3-beta, and blocking it stopped the effect. For your protocol: this is a concrete reason to take gut health and metabolic control seriously — the same fiber-rich, insulin-sensitizing habits that lower ImP are levers you already control.

Lab-grown vessel patches lifted heart function in ischemic pigs within four weeks [The Scientist]

Surgeons can bypass a clogged coronary artery, but there is no standard fix for the tiny microvessels that actually feed heart muscle — and losing capillary density is a hallmark of aging throughout the body. A Stanford team built "vascular organoids" from endothelial progenitor cells drawn from human blood plus smooth-muscle cells derived from bone-marrow stem cells, then layered patches of them onto the hearts of pigs with ischemic heart disease. Over four weeks, treated pigs had better heart function than untreated animals, and their slide toward heart failure was blunted. The patches survived for weeks, raised microvessel density and maturity, and individual cells migrated down into deeper layers of the heart. Pigs are a far closer stand-in for the human heart than mice, which makes this more than a dish result. For your protocol: nothing to do yet, but capillary regeneration is a frontier worth watching — and a reminder that Zone 2 cardio, which grows your own capillaries, is the version available today.

Eight months of dasatinib-plus-quercetin restored Klotho and reversed kidney aging in mice [npj Regenerative Medicine]

Dasatinib (a generic leukemia drug) plus quercetin (a flavonol sold in any supplement aisle) is the original senolytic "hit-and-run" cocktail, and a new multi-omics study followed it long-term in the kidney. Starting at 12 months of age, mice received the D+Q combo by mouth every two weeks for eight months. Treated kidneys showed fewer senescence markers (p16, p21, SA-beta-gal), restored levels of the anti-aging protein Klotho, and less fibrosis and inflammation; single-cell sequencing showed transcriptional aging reversed across multiple kidney cell types. The mechanism traced back to reactivated PPAR-alpha signaling and better fat handling. Two caveats matter: this is mice, not people, and human D+Q trials remain small — and a recent controversy over how many senolytic studies measured the wrong p16 protein means even the biomarker wins deserve a skeptical read. For your protocol: D+Q is real and cheap, but optimal human dosing is still unproven, so treat any personal use as an experiment of one, not a settled protocol.

Brain-waste drainage was already failing in 18 adults with a pre-Parkinson's sleep disorder [npj Parkinson's Disease]

Your brain flushes metabolic waste — including the misfolded proteins behind neurodegeneration — largely during sleep, through the glymphatic system. Researchers used MRI to compare 18 people with isolated REM-sleep behavior disorder (iRBD), a condition that often precedes Parkinson's by years, against 20 healthy young and 18 older controls. The iRBD group had enlarged cerebrospinal-fluid and perivascular-space volumes without the matching drainage capacity seen in normal aging — a signature of fluid backing up rather than clearing. That stasis points to impaired filtration and weaker glymphatic clearance well before any movement symptoms appear. It is a small imaging study, but it reframes sluggish brain-waste drainage as an early, measurable event rather than a late consequence. For your protocol: protect deep sleep, when glymphatic clearance peaks, and treat REM-sleep behavior disorder (physically acting out dreams) as a signal worth raising with a clinician rather than ignoring.

Click here to share your thoughts

Here’s a big helping of unapologetic vegetable hype. Turn it up. 🎶

Underneath the goofy hook is the real idea from the book: you’re an energy system, and every colorful plate is a deposit in your energy account. Eat for energy, and the fog lifts a little.

“Eating for Energy” is one of the chapters in Huna Makia — coming soon. Join the waitlist to be first to know when it launches, and I’ll send you the free one-page Quick-Start Protocol as a welcome.

Join the waitlist →

Daily checklist

Morning — 16 oz water with a pinch of salt · morning light (10–15 min, no sunglasses) · high-protein first meal, 20–30 g (or your fasting window) · record fog, sleep, and energy scores.

Afternoon — protein-containing meal · brief walk after eating (10–15 min) · main exercise session if scheduled and energy allows.

Evening — dinner at least 3 hours before bed · dim lights 2 hours before bed · no screens 1 hour before bed · consistent bedtime.

The idea behind it

Recovery works on two fronts at once: spend less energy on the drains (poor sleep, blood-sugar spikes, chronic stress) and build more capacity (movement, light, protein, purpose). The full four-pillar system, the tiered plan for different energy levels, and the tracking templates are all in the book.

⚠️ When to seek help — Seek immediate care: chest pain or pressure · difficulty breathing · sudden severe headache · neurological symptoms (numbness, weakness, confusion) · any thoughts of self-harm. Schedule an appointment: new or worsening symptoms · no improvement after 4+ weeks · questions about medications or supplements · before making significant changes.

This is one person’s recovery account, not medical advice, and it is not a substitute for care from your own clinician. You’ll be the first to know when the full book — Huna Makia: Energy Flows Where Attention Goes — launches.

© 2026 Anand Karasi. All rights reserved.

Join the waitlist →

How AI and Ancient Wisdom Helped Me Clear the Fog of Long COVID

At a gas-station pump, I couldn’t remember my own ZIP code — a number I’d typed a thousand times. I had designed guidance systems at MIT and built an AI company, and Long COVID had taken the one tool I’d always relied on: my mind.

It took me nearly five years to find my way out. My brain-fog score went from a 9 out of 10 in June 2021 to a steady 3 by January 2026. Huna Makia is the map I wish someone had handed me at that pump.

Here’s the whole book in one sentence: the fog is an energy problem, and you have far more power over your energy than anyone told you. Not willpower — energy, the real physical kind your cells make every second. Grounded in the mitochondrial science of Dr. Martin Picard at Columbia, and built around a Hawaiian principle — huna makia, energy flows where attention goes — the book turns a five-year recovery into a concrete, trackable protocol anyone can follow.

The book is finished and seeking a publisher. While that’s underway, here are two sample chapters.

Read the sample chapters

Prologue: The Five Digits I Couldn’t Remember — https://hunamakia.substack.com/p/prologue-the-five-digits-i-couldnt

Chapter 3: You Are Energy — The Mitochondrial Key — https://hunamakia.substack.com/p/chapter-3-you-are-energy-the-mitochondrial

Get notified when it launches

Subscribe below and you’ll be first to know the moment the book is available — and you’ll get the free one-page Quick-Start Protocol as a welcome.

Table of Contents

Prologue — The Five Digits I Couldn’t Remember

How to Use This Book — Your Path Out of the Fog

Part I — The Crisis: What Long COVID Did to My Brain (Chapters 1–5)

Part II — The Guiding Principle: Meeting the Mentor (Chapters 6–7)

Part III — The Tool: Finding Solutions with AI (Chapters 8–10)

Part IV — The Solution: The Recovery Protocol (Chapters 11–15)

Part V — The Return: Lessons and the Path Forward (Chapters 16–18)

Appendices — protocol summary, tracking templates, AI conversation excerpts, peer-reviewed research, questions for your doctor, and the attention audit

This is a companion page for Huna Makia: Energy Flows Where Attention Goes, a complete book currently seeking a publisher. This is one person’s recovery account, not medical advice.

© 2026 Anand Karasi. All rights reserved.

You are not your body. You are the energy flowing through it.

That sounds like something printed on a yoga studio wall. It is, in fact, one of the more rigorous statements in modern biology, and I first encountered it through the work of Dr. Martin Picard, an associate professor at Columbia University who studies what he named mitochondrial psychobiology — the science of how our inner experience and our cellular energy shape each other. The difference between a living, thinking person and a body that has just died is not the atoms. All the molecules are still there in the moment after death. What has stopped is the flow of energy. We are, as Picard puts it, an energetic process.

The moment I read that, the Hawaiian phrase I had named my company after — Huna Makia, energy flows where attention goes — stopped being a metaphor and became a description of machinery. Because if I am energy, then brain fog is not a mood or a character flaw. It is what it feels like when energy stops flowing properly to the brain.

Let me build the picture from the ground up.

The 5,000 trillion power plants inside you

Inside almost every one of your cells are tiny structures called mitochondria — on average about a thousand per cell, adding up to something like 5,000 trillion in your body. They are the reason you are warm; the reason you can think.

📖 DEFINITION: Mitochondria — the power plants of your cells. They take the food you eat and the oxygen you breathe, strip electrons from that food, and flow them like a tiny electrical circuit toward oxygen — releasing energy that the cell captures as ATP, its universal energy currency. When mitochondria falter, every process they fuel, including thought, runs short of power.

Here is the part most of us were never taught. Mitochondria do far more than make ATP. They behave like a distributed nervous system inside you — covered in receptors, constantly sensing the environment (Is there enough fuel? Is there a stress hormone here? Is there danger?) and signaling to one another. Picard calls them little antennas inside the cell. Your trillions of power plants are also, collectively, a kind of intelligence — one that is exquisitely sensitive to how you live.

And your brain is their single hungriest customer. It is about 2% of your body weight and burns roughly 20% of your energy. No organ is more dependent on a steady, clean supply of power. No organ suffers faster when that supply is disrupted.

The fixed energy budget

The second idea is the one that finally explained my fog. You have a finite energy budget, and your body spends it according to a strict hierarchy of priorities.

Think of it like Maslow’s hierarchy, but for cells. When resources are plentiful, the body funds everything — including the low-priority luxuries of growth, maintenance, and repair. These are the anti-aging processes: clearing damaged proteins from the brain, repairing DNA, replacing worn-out mitochondria, keeping the immune system’s housekeeping current. They matter enormously over a lifetime. But they are not urgent. And when a genuine threat shows up — a lion, a deadline, or a virus — the body does exactly what a business does in a cash crisis: it defunds the long-term projects and pours everything into survival.

Now hold that idea against what a serious infection does.

Why illness feels the way it does

When your immune system is fighting a pathogen, it is one of the most energy-expensive things your body ever does. Your metabolic rate objectively rises — and yet you feel utterly drained. That paradox used to puzzle me until I understood the budget. The energy isn’t gone; it has been reassigned. Your immune system has commandeered it, and it is being pulled away from your brain.

Picard describes catching a flu on a New Year’s Eve — resting heart rate at 110 instead of 60, metabolism roaring — and finding that although he is a scientist who loves thinking about energy, he could not muster the will to open his laptop and write a single line about the very experience he was having. I just didn’t care about anything, he recalls. I was just trying to survive. He compares the mind in that state to the difference between a laser and a bare light bulb: same quantity of energy, but scattered and incoherent instead of focused. His mind had become a diffuse bulb.

Read that description again, because it is the best account of Long COVID brain fog I have ever encountered — and it came from a healthy man with a two-day flu. Everything the biologists call sickness behavior — the exhaustion, the social withdrawal, the loss of motivation, the sense that nothing matters, the wanting to lie under the covers — is not weakness. It is a coordinated energy-conservation strategy, ancient and adaptive, run by your body to free up power for the fight.

The fixed energy budget: when the body fights a chronic illness, energy is rerouted from thinking and repair to defense — and that reroute is what brain fog feels like.

🔑 KEY INSIGHT: Long COVID is sickness behavior that never switched off. If your own antibodies keep triggering low-grade inflammation (Chapter 2), your body keeps the emergency budget in force — permanently defunding the brain and the repair systems. The fog, the fatigue, the flattened motivation, even the depression, are what chronic energy diversion feels like from the inside. You are not lazy. Your power is being spent elsewhere.

This was the reframe that changed how I fought. I stopped trying to push through the fog with willpower — which only demanded more energy from a system already in deficit — and started asking a completely different question: How do I lower the drain, and how do I rebuild the supply? Every protocol in the second half of this book is one answer or the other.

Card inserted. Screen blinking. Please enter ZIP code.

Five digits. The ZIP code of the house I had lived in for years. The number I had typed a thousand times, at this exact pump, without ever once thinking about it. My thumb hovered over the keypad and — nothing. Not a blank where the number used to be. Something worse: the certainty that I knew it, sitting just behind a wall I could not reach. I could feel its shape. I could not find its face.

I stood there, forty-five years old, a man who had designed guidance systems at MIT, who had built an artificial-intelligence company, who had once held whole architectures of code in his head — and I could not remember my own ZIP code to buy gasoline.

That was the moment I stopped being able to pretend.

For months I had been telling myself a story: that I was tired, that I was stressed, that the fog would lift on its own if I just pushed a little harder. The story ended at that keypad. Because you can talk yourself out of fatigue. You cannot talk yourself out of a number that has fallen out of your own mind.

I had survived COVID-19. The fever broke; the cough faded; I counted myself lucky. My friend Ram had not been lucky — he died in a hospital an ocean away, and I will tell you about him. I walked away breathing. But something had stayed behind in me after the virus left. A fog that sleep couldn’t touch. A fatigue that turned a flight of stairs into a negotiation. A brain that had always been my most reliable tool, and suddenly wasn’t.

It would take me nearly five years to find my way out. This book is the map I wish someone had handed me at that pump.

Here is what I learned, compressed into a single sentence: the fog is an energy problem, and you have more power over your energy than anyone told you. Not willpower. Not positive thinking. Energy — the real, physical kind, the kind your cells manufacture every second of your life, the kind that either reaches your brain or doesn’t. I learned to route more of it back to my mind. I did it with an ancient Hawaiian principle for a compass, artificial intelligence for a research partner, and the stubborn belief that a solution existed even when I couldn’t see it.

In June 2021, I rated my brain fog a 9 out of 10. I couldn’t write an email. I shut down my company.

In January 2026, I rate it a 3. I work full days. I run. I ski black-diamond runs with my daughter. I wrote this book.

The distance between those two numbers is what these pages are about. I can’t promise you’ll travel it as I did — your biology is your own. But I can promise you’ll finish this book with something I didn’t have at that gas station: a method, a mechanism, and a reason for hope that is grounded in science rather than wishing.

Let’s begin.

This is a sample chapter from Huna Makia: Energy Flows Where Attention Goes — a complete book currently seeking a publisher. Subscribe below to be the first to know when it launches, and get the free one-page Quick-Start Protocol as a welcome.

© 2026 Anand Karasi. All rights reserved.

A yogurt-and-walking routine slowed biological aging 2.2% in just 12 weeks [Fight Aging]

A randomized controlled trial put overweight men aged 50 to 74 on a deliberately unglamorous 12-week program: walk or use a home stepper for at least 30 minutes on three or more days a week, cut back on overeating and sugary drinks, and eat one 100-gram serving of plain yogurt containing the probiotic Bifidobacterium longum BB536 every day. The intervention group's DunedinPACE — a DNA-methylation measure of how fast you are aging — slowed by an estimated 2.2%, while the control group did not move. That is a small but real shift from cheap, boring inputs, and it is one of the first randomized trials to bend a pace-of-aging clock in only three months. For your protocol: the win here is the stack, not any single hero supplement — pairing a daily probiotic with modest cardio and calorie discipline is exactly the kind of low-cost, low-risk combination worth running for a quarter and re-testing.

Two copies of this centenarian gene variant track with less frailty and younger immunity [Fight Aging]

The longevity-associated variant of the BPIFB4 gene (LAV-BPIFB4) shows up far more often in centenarians than in the general population, and people who carry two copies tend to be less frail with better cardiovascular and immune function. New work maps one reason why: the variant reshapes platelets, raising surface CD47 so they actively suppress monocyte activation and inflammatory signaling instead of feeding it. Strikingly, giving the recombinant BPIFB4 protein to mice reproduced the effect — and the protein is sturdy enough to survive oral delivery. That points toward a future drug that could hand non-carriers some of the anti-inflammatory resilience centenarians are simply born with. For your protocol: there is nothing to buy here yet, but it is a sharp reminder that chronic inflammation is a core aging driver — the boring anti-inflammatory basics (sleep, omega-3s, muscle, dental health) are your current stand-in for a centenarian's genetics.

Two compounds — rapamycin and MitoQ — restored aging lungs' ability to clear scar tissue [Fight Aging]

Pulmonary fibrosis — scarring that stiffens the lungs — climbs steeply with age, and this study pins part of the blame on fibroblasts that lose the ability to digest excess collagen. In aged mice, those cells showed reduced collagen phagocytosis, over-alkaline lysosomes, and elevated mitochondrial ROS, all traced to age-related loss of a regulator called PRDM16. Two interventions reversed the defect: rapamycin, which restored lysosomal function, and mitoquinone — the mitochondria-targeted antioxidant sold as MitoQ — which scavenged the ROS; overexpressing PRDM16 broke the whole mitochondria-lysosome feedback loop. It is a mechanism story in mice, not a human result, but it links two compounds already in the longevity conversation to a concrete repair pathway. For your protocol: file rapamycin and MitoQ under "watch," not "start" — the data are preclinical, but lung resilience is an underrated healthspan target worth tracking.

Senescent cells quietly shut down stem cells across muscle, bone, and marrow [Fight Aging]

A new review lays out the growing evidence that senescent cells do not just sit there leaking inflammatory signals — they actively suppress the stem cells next door. The authors walk through case after case of direct competition between senescence and stemness: mesenchymal stem cells that lose potency as they pick up senescence markers, bone-marrow stem cells whose bone-building differentiation gets blocked, and muscle satellite cells that fail to regenerate tissue. Because clearing senescent cells has repeatedly rejuvenated aged tissue in mice, this reframes senolytics as a way to unshackle your own stem cells rather than only dialing down inflammation. For your protocol: it strengthens the rationale for periodic, hit-and-run senolytic strategies (fisetin, or dasatinib plus quercetin), but human efficacy data are still thin — a reason to follow the trials closely, not to self-dose aggressively.

Old and young "backup" blood progenitors proved functionally identical — unlike their stem cells [Fight Aging]

The blood and immune system is built as a hierarchy: a small pool of hematopoietic stem cells at the root, and larger sets of intermediate progenitor cells descending from them to churn out red and white blood cells. It is well established that the root stem cells accumulate damage with age, which drives immune decline and makes platelets more prone to dangerous clotting. This work found that one progenitor population — Flk2+ multipotent progenitors — reconstituted blood just as well whether taken from young or old mice, with essentially unchanged transcriptomics, proliferation, and mitochondrial capacity. If those resilient progenitors are quietly buffering the loss of stem-cell function, it reshapes where anti-aging efforts in blood should aim. For your protocol: nothing actionable yet, but it is useful context for why age-related clotting risk rises — a nudge toward the vascular basics (movement, not smoking, managing blood pressure) while the cell biology gets sorted out.

A rare disorder of excess DNA methylation mimics aging — with an important catch [Fight Aging]

Most "accelerated aging" syndromes trace back to broken DNA repair and a pile-up of mutations, which is why they only loosely resemble normal aging. Researchers describe a different kind: a rare condition driven by excess DNA methylation that distorts epigenetic control of gene expression, producing features that superficially echo the epigenetic drift of ordinary aging. That makes it a tempting natural experiment for the popular idea that epigenetic change is a root cause of aging — but the authors flag the catch, that superficial resemblance is not proof of a shared mechanism. For your protocol: treat it as a healthy caution for the enthusiasm around epigenetic reprogramming and methylation clocks — these markers are powerful readouts, but a number moving on a clock is not the same as reversing the biology underneath it.

Click here to share your thoughts

An old antidepressant stretched aged mice's median lifespan 17.5% by plugging calcium leaks [Lifespan.io]

In Nature Communications, Chinese researchers traced a chain from leaky calcium stores to DNA damage: with age, cytoplasmic calcium rises through the ER's IP3R channel, elevating a protein called S100A6 that degrades the DNA-repair enzyme PARP1 and triggers cGAS-STING inflammation. Mianserin, a decades-old antidepressant that blocks the serotonin receptors feeding that channel, reversed the cascade. Given every other day for four months to naturally aged mice, it extended median survival by 17.5% and improved fur, posture, and movement; in fast-aging progeroid mice started at four weeks, it added about 30%. The caveats are real — cohorts were tiny (7–8 mice per group) and all male. For your protocol: this is early mechanism, not a prescription to chase — mianserin is a sedating psychiatric drug, and the signal here is that calcium handling is emerging as a druggable aging lever, not a green light to self-experiment.

An 8-hour eating window added 12% to male mice's lifespan — but they ate 23% less [Lifespan.io]

A new University of Texas study in Nature Aging put 528 lean mice on lifelong time-restricted feeding to ask the question the fasting field keeps dodging: is it the clock, or just the calories? An 8-hour nightly window raised median lifespan 12% and maximum lifespan 3% — but only in males, and those mice voluntarily ate 9–23% less, muddying whether the benefit came from timing or from mild caloric restriction. A 12-hour window, which caused little calorie cutting, produced no lifespan gain at all, though a 31-item frailty/healthspan index improved in both sexes on both schedules. Blood glucose, leptin, and inflammatory cytokines were largely unchanged, suggesting the benefits don't run through big shifts in systemic signaling. For your protocol: in mice, the shorter window's lifespan edge looks largely like disguised calorie restriction — a useful reality check given how uneven time-restricted eating has been in human trials.

A third of muscle-loss proteins also drive bone loss — and too much muscle backfires [Lifespan.io]

Mining UK Biobank data in Aging Cell, researchers found that sarcopenia (muscle loss) and osteoporosis (bone loss) each raise the risk of the other, especially in men. Nearly one-third of the proteins associated with either condition were tied to both — almost always in the same direction — and 12 shared genetic regions turned up, 10 positively correlated, many funneling through NF-κB inflammation. The twist was a U-shaped curve: people with very low muscle mass had weaker bones, but so did those with excessive muscle, which the authors attribute to overloading bone through too-hard or poorly designed training. Omega-3-to-total-fat ratios, smoking, short sleep, and poor gut health all showed up as mediators, though this is association-only (grip strength and heel measures, no causality). For your protocol: load your skeleton with resistance training, but don't assume more is always better — recovery, sleep, and omega-3 status appear to sit on the shared muscle-bone axis.

Across 37,500 brain scans, glucose was the No. 1 blood driver of an older-looking brain [Medical Xpress]

Writing in Molecular Psychiatry, teams at Jilin University and China Medical University trained a machine-learning "brain age" model on more than 4,000 healthy people, then computed the gap between brain and chronological age for roughly 37,500 UK Biobank participants. In the 21,780 with metabolite data, nine blood molecules tracked with faster-aging brains — and glucose showed the strongest effect of all. Higher glucose was also linked to smaller volumes across 80 cortical, subcortical, and cerebellar regions. Because it's observational, this shows correlation, not proof that lowering glucose rejuvenates the brain. For your protocol: it reinforces glucose control — through diet, post-meal movement, and weight management — as one of the few brain-aging levers you can actually pull, and it dovetails neatly with this week's fasting data.

Mars-level radiation aged mouse livers in 24 hours, echoing the NASA Twins Study [News-Medical]

A University of Central Florida team publishing in GeroScience used spaceflight as an accelerated-aging model, exposing mice to 14 days of simulated microgravity plus galactic-cosmic-radiation doses approximating a round trip to Mars. The liver responded within a day: just 24 hours after radiation, gene-expression changes "remarkably similar" to normal aging appeared, alongside rising cellular senescence, inflammation, and fibrosis. The pattern matched genetic signatures pulled from real astronaut blood in the NASA Twins Study and the Inspiration4 mission, and the changes converged on miRNA–TGF-β networks. The researchers then tested antagomirs — molecules that silence specific microRNAs — as a possible countermeasure. For your protocol: nothing to swallow here, but it's a vivid reminder that radiation and senescence pathways can drive measurable aging fast — and it hands geroscience a new, rapid model for stress-testing interventions.

Click here to share your thoughts

Longevity Protocol

This newsletter is focused on bring stories that can help improve longevity. Emerging technologies like AI can help improve longevity. This newsletter highlights data that indicates the direction the technology for longevity is headed.

In this weekly roundup for July 1-8, 2026, I break down three longevity signals worth paying attention to right now:

- Aging damage appearing to vary across roughly seven orders of magnitude across species

- Alpha-ketoglutarate users tracking 1.8 years younger in a 4,200-person dataset

- Long-lived families showing a roughly 13-year cardiometabolic advantage, alongside rare gene signals tied to healthy aging

Why subscribe to the newsletter:

If you want signal over hype in longevity, the Longevity Protocol newsletter helps you track the studies, numbers, and mechanisms most likely to shape real-world thinking before they become mainstream talking points. This week’s stories point to a field becoming more measurable, more mechanistic, and more actionable.

Covered in this video:

1. Aging’s Damage Spans 7 Orders of Magnitude; 2,000 Longevity Genes Stalled

2. Alpha-Ketoglutarate Tracked 1.8 Years Younger; 370 Drugs Flagged for Aging

3. A Butterfly Aged 25x Slower; Long-Lived Genes Bought 13 Years

Newsletter links for this week’s posts:

- Aging’s Damage Spans 7 Orders of Magnitude; 2,000 Longevity Genes Stalled: https://hunamakia.substack.com/p/agings-damage-spans-7-orders-of-magnitude

- Alpha-Ketoglutarate Tracked 1.8 Years Younger; 370 Drugs Flagged for Aging: https://hunamakia.substack.com/p/alpha-ketoglutarate-tracked-18-years

- A Butterfly Aged 25x Slower; Long-Lived Genes Bought 13 Years: https://hunamakia.substack.com/p/a-butterfly-aged-25x-slower-long

If this briefing is useful, subscribe to the newsletter, like this video, and comment on what I should cover next.

Disclaimer:

This is an AI avatar. All content is sourced by, edited and the video produced by AI. If you want to use the data for making decisions please independently verify the sources and the data before use.

Hashtags

#Longevity #HealthyAging #Biohacking #Healthspan #AgingResearch #Biotech #PrecisionHealth #Substack

Disclaimer

This is an AI avatar. All content is sourced by, edited and the video produced by AI. If you want to use the data for making decisions please independently verify the sources and the data before use.

Aging's damage engine spans 7 orders of magnitude, and humans run on a different setting than mice [Nature Aging]

A new modeling study fit the "saturating removal" damage model to survival curves across yeast, worms, flies, mice, dogs, cats, guinea pigs and humans, and found the single parameter that best predicts a species' lifespan is not how fast it repairs damage but how fast it produces it, a rate that varies across roughly seven orders of magnitude. Removal rate, noise and death threshold were near-universal; production was the lever. The model also splits animals into two camps: "ballistic agers" (yeast, worms, flies, mice) where damage outruns removal, and "quasi-steady-state agers" (humans, dogs, cats, guinea pigs) where damage tracks a moving set point. That formalizes something biohackers keep relearning the hard way: mouse lifespan wins often do not port to people. For your protocol: treat dramatic rodent-only results as hypotheses, not instructions, and weight human data far more heavily.

2,000-plus genes can extend life in the lab, and almost none can be delivered into your body yet [Trends in Molecular Medicine]

A new review tallies more than 2,000 genes linked to longer life across model organisms, then explains why that has not produced a shelf of anti-aging gene therapies: delivery. Getting a vector like AAV to express safely across most inner organs, or body-wide from a single IV dose, remains unsolved, and high-dose systemic vectors have caused deaths, so developers avoid them outside severe disease. The therapies that do reach the clinic exploit narrow tricks, such as turning a few fat cells into factories for circulating proteins like klotho or follistatin, or intranasal AAV to reach the brain. Even partial epigenetic reprogramming, the field's great hope, inherits the same delivery problem plus tissue-specific dosing headaches. For your protocol: when a longevity "gene therapy" is marketed to you, the first question is not the gene, it is whether it can actually reach the tissue that matters.

The muscle sensor that makes exercise pay off fades with age, and sulforaphane switched it back on in mice [Science Advances]

Researchers report that NOX4, an enzyme that generates the reactive-oxygen signal muscle uses to adapt to exercise, declines with age in both mice and humans, blunting the payoff from training. Deleting NOX4 in mouse muscle did not just stop growth; it drove overt sarcopenia, frailty, higher body fat, whole-body insulin resistance and even liver disease. Crucially, the decline was reversible: restoring NOX4 with a viral approach, or activating its downstream partner NFE2L2 with sulforaphane (the broccoli-sprout compound), reinstated the adaptive response otherwise triggered by exercise. It reframes part of age-related "anabolic resistance" as a broken redox signal rather than simple wear. For your protocol: the training stimulus is still non-negotiable, and cruciferous or sulforaphane intake is a low-risk bet, though note the rescue so far is in mice.

One longevity gene's collapse ages the male reproductive tract, and stem-cell exosomes reversed it in primates [Protein & Cell]

In aging non-human primates, single-nucleus profiling of the epididymis (where sperm mature) pinned much of the decline on principal cells losing the longevity transcription factor FOXO1. When FOXO1 falls, its FOXO1-LHX1 axis can no longer hold back cellular senescence, and the resulting inflammatory secretions drive fibrosis and functional loss. Restoring the pathway with senescence-resistant mesenchymal progenitor cells or their exosomes reversed several epididymal aging features and brought FOXO1 back, both in living animals and in human epididymal cells. It is an early but clean example of a single regulator sitting upstream of an organ's aging. For your protocol: nothing to act on yet, but it strengthens the case that senescent-cell burden, not just hormones, shapes male reproductive aging.

Your age spots are clusters of senescent cells, biopsies from 9 people confirm [Journal of Investigative Dermatology]

A dermatology team biopsied both age-spot (senile lentigo) and neighboring normal skin from 9 donors and found the pigmented lesions loaded with senescence hallmarks: elevated p16INK4A, lost lamin B1 and enlarged nuclei, pointing to UV-driven senescent cells as a driver of the spots rather than just excess melanin. That reframes a purely cosmetic nuisance as a visible readout of accumulated cellular senescence in sun-exposed skin. It also hints at why senolytic and sun-protection strategies keep surfacing in skin-aging research. For your protocol: daily broad-spectrum sun protection remains the highest-leverage move, and age spots are worth reading as a marker of cumulative photo-senescence, not a standalone flaw.

A month of intermittent hypoxia aged old mice's organs, and a jump to 5,260m aged people fast [npj Aging]

Intermittent mild hypoxia is often sold as a hormetic longevity hack, but this study exposed adult (11-month) and old (23-month) mice to a month of it and saw epigenetic-age acceleration in the lungs, spleen and heart, in the old mice only. The good news: the acceleration reversed once the mice returned to normal oxygen, tracking oxygen-sensitive chromatin (bivalent and PRC2) sites. Human data from the AltitudeOmics project, where 19 adults rapidly ascended to 5,260 meters, showed the same rapid, conserved epigenetic-aging signal. The message is nuance, not panic: oxygen swings are a real, reversible modulator of epigenetic age, and the effect may hit older tissue harder. For your protocol: if you use altitude tents or hypoxic conditioning, treat aggressive protocols with more caution as you age, and do not assume "hormesis" is uniformly beneficial.

Click here to share your thoughts

Alpha-Ketoglutarate Users Tracked 1.8 Years Younger Across 4,200 People [NutraIngredients]

Researchers at the National University of Singapore cross-referenced 84 supplements against saliva-based epigenetic age tests from more than 4,200 people. Delayed-release calcium alpha-ketoglutarate (the Rejuvant formulation, which also carries vitamins A and D3) stood out: its 143 users averaged 1.8 years lower biological age than non-users, and the gap held after adjusting for weight, exercise, and alcohol. The honest caveat is that the longitudinal slice of just 26 people showed no significant change over time, so this is a strong correlation, not proof. AKG is a citric-acid-cycle molecule that declines with age and has extended lifespan in flies and mice. For your protocol: AKG remains one of the better-evidenced longevity supplements, but treat 1.8 years as an association to watch, not a guarantee.

Screening 6,442 Drugs, a Network Map Flagged 370 That May Target Aging [Lifespan.io]

A Northeastern and Harvard team led by network scientist Albert-Laszlo Barabasi mapped 6,442 approved drugs onto the Hallmarks of Aging using a human protein-interaction network of over 500,000 links. Their SHARP pipeline flagged 370 compounds close enough to a hallmark to plausibly perturb it, including 83 network drugs that act only indirectly. As validation, all 8 drugs that extended mouse lifespan in the rigorous Interventions Testing Program scored positive, while fewer than half of the failures did. Strikingly, aspirin mapped to 6 hallmarks and dasatinib to 5, but rapamycin touched only 1. For your protocol: this is a candidate-generation tool, not a prescription, but it argues that a drug's breadth across aging hallmarks may matter more than its reputation.

Fast-Aging Brain Cells Tripled Alzheimer's Risk Across 60,000 People [Lifespan.io]

Stanford's Tony Wyss-Coray and colleagues built machine-learning clocks for more than 40 individual cell types by reading their protein signatures in blood, then tested them across roughly 60,000 people. Aging was strikingly uneven: 35 percent of people had no extreme age gaps in any cell type, while 1.5 percent showed extreme aging in ten or more. The payoff was in prediction. Among APOE4 homozygotes, those with rapidly aging astrocytes were nearly three times as likely to develop Alzheimer's, and accelerated skeletal-muscle-cell aging flagged ALS more than three years before diagnosis. For your protocol: a single whole-body biological age number is getting too blunt to act on, and organ-by-organ aging is where useful diagnostics are heading.

41 Human Trials Ranked What Lowers Biological Age; Rapamycin Missed [Fight Aging]

A new systematic review pooled 41 human studies that measured next-generation epigenetic clocks, the kind most tied to mortality, before and after an intervention. The approaches that consistently lowered epigenetic age were unglamorous: exercise, a plant-rich diet, caloric restriction, omega-3s, a multivitamin-mineral, the GLP-1 drug semaglutide, umbilical-cord plasma, and the statin pitavastatin. More provocative were the misses: nicotinamide riboside, rapamycin, and senolytics showed no detectable effect on these clocks, and plasmapheresis actually accelerated measured aging. For your protocol: the boring basics still carry the strongest human epigenetic data, and several buzzy interventions do not yet move these clocks, though a null clock result is not the same as no benefit.

A Human-Only RNA That Mice Lack Drove Senescence in 7 Tissues [Aging Cell]

Human genomes carry roughly three times more long non-coding RNA than mice, and this study zeroed in on one strand, LINC01021, that has no mouse equivalent. Its expression shifted with age across 7 tissues, and forcing it higher pushed human fibroblasts into senescence while silencing it protected them. Mechanistically it suppresses a protein called RBMX, which in turn raises the senescence driver p53. When researchers knocked the human gene into mice, the animals grew frail earlier, with weaker grip strength and more inflammation. For your protocol: nothing to take here yet, but it is a sharp reminder that mouse studies can miss human-specific aging drivers entirely, so stay skeptical when a rodent result is sold as a finished human answer.

Blocking One Protein Cut 3 Kidney-Failure Markers in 4 Weeks [Fight Aging]

A monoclonal antibody called AD-NP1, already cleared by the FDA for a Phase 1 heart-repair trial, turns out to help a second organ. It blocks ENPP1, a protein that injured tissue releases to stall energy production and healing. In mice given kidney-damaging drugs, blocking ENPP1 sped repair and reduced scarring, and after 4 weeks the three standard markers of kidney failure (creatinine, BUN, and cystatin C) were sharply lower than in controls. For your protocol: this is early animal work, but a regeneration approach that already has a human safety trial underway is worth tracking, especially since kidney function is an underrated longevity lever.

Click here to share your thoughts

Kids of long-lived parents got cardiometabolic disease 13 years later; 12 rare genes surfaced [ScienceDaily]

Researchers analyzing 212 long-lived sibships from the Leiden Longevity Study reported that middle-aged people with long-lived parents developed cardiometabolic disease on average 13 years later than their partners with shorter-lived parents. Sequencing pinned the advantage to four regions of the genome and 12 rare protein-altering variants, including one in the cGAS gene already tied to the inflammatory side of aging. This is the clearest signal yet that a meaningful share of healthspan is heritable, not just behavioral. The variants are rare, so this will not become a supplement, but it points future drug targets at inflammation and DNA-sensing pathways. For your protocol: you cannot pick your genes, but the same cGAS-driven inflammaging these families seem to dodge is the target you can chip at now with sleep, exercise, and inflammation control.

A butterfly that lives 348 days, 25x its cousin, barely ages at all [Phys.org]

A University of Bristol team in Nature Communications clocked a 25-fold gap in maximum lifespan between closely related tropical butterflies: Heliconius hewitsoni reached 348 days while its relative Dione juno lasted about 14. On average Heliconius species live roughly three times longer than their nearest cousins, and at least one, H. hecale, showed little or no physiological decline with age. The leading hypothesis is diet: Heliconius uniquely eat pollen, not just nectar, though H. hecale still outlived its relative even without it. That makes this genus a powerful new model for how aging itself can be slowed rather than just survived. For your protocol: the practical lesson is mechanistic, not a hack, but it reinforces that nutrient quality, not just calories, can reshape the aging trajectory.

One mitochondrial protein stretched mouse lifespan 6.6% and rebuilt muscle and fat [ScienceAlert]

Japanese researchers reported in Aging Cell that mice engineered to make more of the protein COX7RP lived 6.6% longer on average. The protein helps assemble mitochondrial respiratory supercomplexes, and the engineered tissue produced more ATP, carried higher NAD+, and showed lower reactive oxygen species and less of the senescence marker beta-galactosidase in fat tissue. Functionally the animals had stronger muscles and healthier fat, the two tissues that fail fastest with age. It is a clean demonstration that improving the efficiency of energy production, not just the quantity, can extend healthspan. For your protocol: it is the mechanistic case behind why NAD+ support and mitochondrial-density work like zone 2 cardio keep showing up, supercomplex assembly is the lever they are all pulling on.

Two daily beet shots lowered blood pressure in 2 weeks, only in the over-60s [Discover]

A University of Exeter crossover trial gave 36 adults in their 60s and 70s and 39 adults under 30 concentrated nitrate-rich beetroot juice twice a day for two weeks. Blood pressure dropped in the older group but not the younger one, and the effect tracked with a shift in the mouth microbiome: the bacterium Prevotella fell while health-linked Neisseria rose. The takeaway is that the benefit runs through oral bacteria converting dietary nitrate, a step that falters with age and that antiseptic mouthwash can blunt. It is a rare case where a cheap food intervention has a clear, measurable mechanism in older adults specifically. For your protocol: if you are over 60, a daily nitrate source like beetroot or leafy greens is one of the better-evidenced vascular moves, and skip the antibacterial mouthwash that wipes out the bugs doing the work.

A computer-designed molecule extended worm lifespan 30% with no rodent toxicity [RSC Medicinal Chemistry]

A virtual screen aimed at the proton-coupled folate transporter turned up a drug-like molecule, MPOL_B_1, that extended the lifespan of C. elegans by up to 30%. The compound had favorable properties in cell tests and showed no toxicity in mice and rats, the usual graveyard for promising worm hits. Targeting folate transport is an unusual angle that ties one-carbon metabolism, the same pathway methylation clocks read, directly to lifespan. It is early and worm-stage, but a clean safety profile in two rodent species is exactly what most longevity compounds lack. For your protocol: nothing to take yet, but watch the folate and one-carbon metabolism space, it is quietly becoming one of the more credible small-molecule routes to aging biology.

Aged muscle stem cells carry 3.5x more of a repair-braking protein, and removing it has a cost [UCLA Health]

UCLA scientists found that a protein called NDRG1 climbs to 3.5 times higher levels in old muscle stem cells than young ones, acting as a brake on the growth-promoting mTOR pathway. When they blocked NDRG1 in aged mice, the stem cells immediately repaired injury like young cells again, but fewer of them survived over repeated injuries. The catch reframes aging as a survival trade-off: cells slow down on purpose to last longer, so flooring the gas pedal speeds repair at the price of durability. It is a useful caution for anyone chasing maximal mTOR or growth signaling. For your protocol: this is why cycling, not constantly maxing, anabolic signals like mTOR matters, periods of activation for repair balanced with rest beats permanently pushing the accelerator.

Click here to share your thoughts

Biological aging ran slowest between 6.4 and 7.8 hours of sleep, across 17 organ systems [Nature]

A Columbia-led team built a "Sleep Chart" by pairing self-reported sleep duration with 23 biological aging clocks spanning 17 organ systems in roughly 500,000 UK Biobank adults. Aging ran slowest in a narrow window between 6.4 and 7.8 hours a night; both under 6 hours and over 8 hours tracked with faster aging, more disease, and higher mortality risk in a U-shaped curve. The pattern showed up across nearly every organ, not just the brain, and short sleep was specifically tied to depression, type 2 diabetes, hypertension, and heart disease. For your protocol: treat 6.4 to 7.8 hours as a hard target, and block an 8-hour sleep opportunity to reliably bank 7 quality hours.

A topical senolytic fully healed wounds in 80% of aged mice, versus 56% untreated [Aging]

Boston University researchers rubbed the senolytic drug ABT-263 onto the skin of 24-month-old mice for five days, clearing senescent "zombie" cells and switching on collagen, blood-vessel, and tissue-remodeling genes. By day 24, 80% of treated mice had fully closed test wounds, compared with 56% of untreated controls. The effect was specific to aged skin - young skin, with few senescent cells to clear, did not respond - and a topical route sidesteps the systemic toxicity that limits oral senolytics. For your protocol: this is still preclinical, but it points to a precise, local way to prime aging skin before surgery or for slow-healing chronic wounds.

Resistance training shrank the old-versus-young strength gap from 59% to 38% [GeroScience]

Analyzing muscle biopsies from two independent cohorts before and after progressive resistance training, researchers found the program reversed much of aging's transcriptomic signature, pulling senescence-associated and ATF4 stress-pathway genes back toward youthful levels. Before training, older adults were 59% weaker than young controls; after sustained training, that gap narrowed to 38%. The genes that shifted most strongly governed mitochondrial function, the system that erodes most with age. For your protocol: progressive resistance work does more than build strength - it appears to rewrite the molecular aging program in muscle, so make it a non-negotiable rather than a cardio afterthought.

Centenarians carry 37 blood proteins frozen at a youthful signature [Aging Cell]

Profiling plasma from the Swiss SWISS100 centenarian cohort against hospitalized 80-to-90-year-olds and healthy 30-to-60-year-olds, researchers flagged 583 differentially expressed proteins - and within them, a core set of 37 that stayed at a youthful, younger-than-expected level in the centenarians. These youth-associated proteins clustered in immune regulation and oxidative-stress response, suggesting extreme longevity reflects active maintenance of molecular balance, not just luck. The implicated pathways spanned programmed cell death, extracellular-matrix stability, and neurotrophic signaling. For your protocol: it is a blood map of what aging well looks like, and it reinforces that taming inflammation and oxidative stress is where the durable longevity levers sit.

Disabling one fat-burning organelle erased 100% of dietary restriction's lifespan benefit [Nature Aging]

In C. elegans, researchers traced metabolic aging to peroxisomes - the organelles that burn fat - and their import protein PRX-5. As the worms aged, peroxisomal import declined, fat-burning stalled, lipid droplets piled up, and mitochondria faltered. Degrading PRX-5 reproduced metabolic aging, while boosting it preserved lipid handling and mitochondrial integrity and extended life; critically, knocking out peroxisomal import abolished the entire lifespan gain normally delivered by dietary restriction. That makes peroxisomal function a causal hub linking fasting, fat metabolism, and longevity. For your protocol: it is a worm study, but it sharpens the mechanistic case that fasting and caloric restriction work partly by keeping your fat-burning organelles young.

Spermidine failed to beat placebo on memory in a 100-person, 12-month trial [JAMA Network Open]

Spermidine, a polyamine concentrated in wheat germ and aged cheese, is a popular autophagy-boosting supplement - but its best human test came up empty. The randomized, placebo-controlled SmartAge trial followed 100 older adults with subjective cognitive decline for 12 months and found no significant memory benefit over placebo. An earlier, smaller 3-month study of 85 nursing-home residents had shown modest gains on a cognitive battery, but the longer, larger trial did not replicate it. The autophagy rationale and the epidemiology are still intriguing; the hard clinical proof in people is not. For your protocol: spermidine is low-risk and food-derived, so keep it if you like, but do not bank on measurable cognitive gains - the strongest RCT showed none.

Click here to share your thoughts

In this episode, we cover key signals across tissue repair, stem cell rejuvenation, mitochondrial health, metabolic resets, biological age clocks, rapamycin, senolytics, GLP-1-related aging research, and the growing flow of capital into longevity companies.

The big takeaway: longevity science is shifting from vague anti-aging promises toward an engineering mindset — identify the mechanism, measure the biological change, improve the protocol, and scale what works.

Topics covered:
• Blood stem cell rejuvenation and immune resilience
• Rapamycin and aging hearts
• Choline, NMN, NAD+, diet timing, and metabolic pathways
• Senolytics, Yamanaka factors, GlyNAC, and systemic aging
• Biological age clocks and why better measurement matters
• Why investors are backing longevity as a serious emerging industry

Subscribe to the Hunamakia newsletter for more evidence-led breakdowns on longevity science, healthy lifespan extension, anti-aging research, and the business of human healthspan:

Longevity Protocol

This newsletter is focused on bring stories that can help improve longevity. Emerging technologies like AI can help improve longevity. This newsletter highlights data that indicates the direction the technology for longevity is headed.

Like, subscribe, and comment with the longevity topic you want covered next.

#Longevity #AntiAging #Healthspan #Biotech #Rapamycin #Senolytics #StemCells #BiologicalAge #NAD #LongevityScience